Search | IOVS | ARVO Journals

View

Showing 1 – 5 of 5

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

Psychometric properties of the Vision Impairment in Low Luminance (VILL) questionnaire in age-related macular degeneration in the MACUSTAR study

Jan Henrik Terheyden; Susanne Gunda Pondorfer; Charlotte Behning; Moritz Berger; Donna Rowen; Jill Carlton; Frank G Holz; Thomas Butt; John E. Brazier; Robert Patrick Finger

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3500. doi:

ARVO Annual Meeting Abstract June 2015

Ranibizumab Therapy for Neovascular AMD in eyes with good vision (>6/12): visual outcomes and cost-effectiveness based on real world outcomes of 92,976 treatment episodes

Adnan Tufail; Cecilia S Lee; Aaron Lee; Catherine A Egan; Dawn A Sim; Robert Johnston; Thomas Butt; UK AMD EMR Users Group

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5365. doi:

ARVO Annual Meeting Abstract April 2014

Estimating Health State Utility Values Associated With AMD Using A Combined Visual Function Algorithm

Thomas Butt; Gary S Rubin

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):180. doi:

ARVO Annual Meeting Abstract June 2013

Comparing Patient and Public Preferences for Health States Associated with Age-Related Macular Degeneration

Thomas Butt; Hannah Dunbar; Steve Morris; Shepley Orr; Gary Rubin

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4419. doi:

ARVO Annual Meeting Abstract March 2012

Cost Effectiveness Of Bevacizumab (Avastin) For AMD: A Comparison Of Visual Acuity And Contrast Sensitivity Outcomes

Thomas Butt; Praveen J. Patel; Adnan Tufail; Steve Morris; Gary S. Rubin

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1414. doi:

Advertisement